TX-FLUENCE
21.9.2022 15:11:14 CEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, has been selected by Wageningen University & Research (WUR) as the LED technology partner for its new Netherlands Plant Eco-phenotyping Centre (NPEC). In NPEC’s state-of-the-art phenotyping greenhouse, VYPR DUO 3x2 fixtures are used to support research on genotype-phenotype associations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005421/en/
In NPEC’s state-of-the-art phenotyping greenhouse, VYPR DUO 3x2 fixtures are used to support research on genotype-phenotype associations. (Photo: Business Wire)
The official opening of NPEC will take place preceding the weeklong International Plant Phenotyping Symposium 2022 (IPPS 2022), held from Sept. 26 to Sept. 30 in Wageningen, Netherlands. Fluence, a Gold Sponsor of IPPS 2022, will attend the conference and opening of NPEC in Wageningen.
NPEC consists of six modules across two university campuses, each offering dedicated phenotyping platforms with its own measurement systems. A specialized greenhouse at the WUR campus houses five climate-controlled compartments outfitted with Fluence’s VYPR DUO 3x2 fixtures. The compartments’ 3D and hyperspectral imaging, conveyor systems and various sensors produce high-precision measurements—including plant size, color and leaf positioning—that can be examined to understand the genetic response of plants to varied conditions and treatments, such as heat, drought or increased soil salinification.
“Using highly customizable technologies that generate high-quality plant performance data on how environmental parameters affect the plant phenotype was a key requirement when selecting our equipment partners,” said Rick van de Zedde, senior scientist and project manager for NPEC. “Having worked with Fluence for the lighting in our Serre Red high-tech quarantine greenhouse, we knew PhysioSpec™️ BROAD R4 white spectrum fixtures could help establish a near-ideal research environment in the NPEC greenhouse.”
In addition to Fluence’s VYPR top lights, which feature PhysioSpec™️ BROAD R4 white spectrum, NPEC researchers will use the Maxi-MARVIN imaging cabinet to assist in research, a high-throughput 3D modeling system developed by WUR that can reconstruct a plant’s architecture within milliseconds. Other high-tech research tools at WUR include a dark and light adaptation chamber and imaging systems capability to analyze the photosynthetic efficiency of plants.
“Establishing research on genotype-phenotype associations, specifically how ecological and environmental variables impact the plant phenotype, is essential for the development of novel, climate-proof crops,” explained van de Zedde. “Automated phenotyping will also allow for a dramatic increase in the speed of plant breeding and time to market for novel crop varieties.”
“We are honored to partner with WUR to advance the future of high-quality food production and sustainability in cultivation,” said Theo Tekstra, Fluence’s technical director for Europe, the Middle East and Africa and team lead for the WUR project. “Our PhysioSpec™️ BROAD R4 white spectrum came closest to what the WUR scientific team defined as an ideal spectrum to do year-round research on a wide range of plant species.”
Fluence's continuing partnership with WUR also includes LED fixtures in a specialized greenhouse for insect research and phenotyping climate rooms at Wageningen. Read more about Fluence’s collaborations with WUR here.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom